Zenas Biopharma Inc’s recent filing unveils that its Chief Executive Officer MOULDER LEON O JR acquired Company’s shares for reported $0.82 million on Jan 07 ’26. In the deal valued at $16.38 per share,50,000 shares were bought. As a result of this transaction, MOULDER LEON O JR now holds 316,155 shares worth roughly $6.37 million.
Then, MOULDER LEON O JR bought 30,000 shares, generating $489,000 in total proceeds. Upon buying the shares at $16.30, the Chief Executive Officer now owns 346,155 shares.
Before that, MOULDER LEON O JR bought 20,000 shares. Zenas Biopharma Inc shares valued at $331,000 were divested by the Chief Executive Officer at a price of $16.55 per share. As a result of the transaction, MOULDER LEON O JR now holds 366,155 shares, worth roughly $7.38 million.
Morgan Stanley downgraded its Zenas Biopharma Inc [ZBIO] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Wolfe Research began covering ZBIO with “an Outperform” recommendation on February 04, 2025. H.C. Wainwright started covering the stock on December 16, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Friday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock jump 1.15% to $20.16. Over the last five days, the stock has gained 25.37%. Zenas Biopharma Inc shares have risen nearly 148.58% since the year began. Nevertheless, the stocks have fallen -44.48% over the past one year.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2025-12-31, dropping by 79536.0 shares to a total of 4.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 4.86 million shares. There was a decline of -1.66%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 05, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $34 price target.
